MHRA Admits UK Medtechs Exposed To Risks As It Consults On Brexit No-Deal Impact
Executive Summary
The UK Medicines and Healthcare products Regulatory Agency is now consulting, in detail, on what a no-deal Brexit could look like and how it would impact manufacturers and the MHRA itself. Companies have less than four weeks to respond.
You may also be interested in...
Helping Hand: A Guide To The New UK Consultations On No-Deal Brexit Regs
With just over three weeks to provide input on the UK's proposed regulatory response to the prospect of a no-deal Brexit, Medtech Insight unravels key messages from the four documents issued by the Medicines and Healthcare products Regulatory Agency (MHRA), condensing 127 pages into the main points to aid industry in providing feedback. There's no time to waste for those wishing to influence the outcome.
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.